Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

Contributed by: Business Wire

Logo

Tags

Technology

Finance

Other Technology

Professional Services

Business

Biotechnology

General Health

Pharmaceutical

Health

Oncology

Myricx Bio

More Like This

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support

Sofinnova Partners Closes €650M ($750M) Capital XI, Greatly Exceeding Initial Target to Back Early-Stage Healthcare Deals

Sofinnova Partners Raises €1.2 Billion to Fuel the Next Wave of Life Sciences Innovation

Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's Proprietary Linker Technology

Edward Kliphuis, Partner, Sofinnova Digital Medicine Strategy and Simon Turner, Partner, Sofinnova Digital Medicine Strategy (Photo: Sofinnova Partners)

Sofinnova Partners Raises $200M Digital Medicine Fund